Coya Therapeutics Inc
Coya Therapeutics Inc (COYA) Implied Volatility Current
COYA's 30 day implied volatility is 436.97%, with an IV Rank of 90.08%. This is a high IV Rank versus the past year, meaning Coya Therapeutics Inc options are relatively expensive and currently favor sellers. COYA's 30 day historical volatility sits at 75.12%, which means implied volatility is running 361.85 points above historical volatility, as of Nov 16, 2026.
Read more
Tracking COYA implied volatility helps you spot when Coya Therapeutics Inc options are historically cheap or expensive, and where the best trades are hiding. When COYA IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor COYA implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking COYA IV rank helps you see whether COYA's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases.
Implied Volatility
IV is highly elevated. Premiums are expensive, strongly favoring sellers.
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →